Lead Product(s) : Methyldopa
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IM Therapeutics Reports Positive Results in Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes
Details : Each group had six subjects receiving doses of IMT-002 between 350 mg and 1050 mg administered as a once-daily or twice-daily regimen over a two-week duration. Six people received placebo and were interspersed in the four groups.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2021
Lead Product(s) : Methyldopa
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methyldopa
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study will compare IMT-002 vs placebo for safety, tolerability and pharmacokinetic profiles. IMT-002 has been developed as a selective HLA-DQ8 blocker based on extensive computational work, in vitro and in vivo characterization.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Methyldopa
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methyldopa
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IM Therapeutics Announces First Patient Dosed in Ph1 Study IMT-002
Details : The trial is designed as a single ascending dose (SAD) Phase 1a study of healthy subjects to demonstrate drug safety and tolerability.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Methyldopa
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methyldopa
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations
Details : Methyldopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 06, 2017
Lead Product(s) : Methyldopa
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methyldopa
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Government Medical College, Nagpur | Daga Memorial Women's Hospital, Nagpur, India | University of British Columbia | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
Details : Methyldopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension, Pregnancy-Induced.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2013
Lead Product(s) : Methyldopa
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Government Medical College, Nagpur | Daga Memorial Women's Hospital, Nagpur, India | University of British Columbia | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
